Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice.
Trinidad Montero-VílchezLuis Salvador-RodriguezManuel Sanchez-DiazCarlos Cuenca-BarralesAntonio Martinez-LopezSalvador Arias-SantiagoMolina-Leyva AlejandroPublished in: Dermatologic therapy (2020)
In our population, the external validity of current eligibility criteria for clinical trials is low. Most patients receiving adalimumab in real-life setting would not be eligible for clinical trials.